|
Losartan does not interfere with the metabolism and uptake of MPTP. |
||
| (a) MPP+ levels in the striatum and substantia nigra of C57BL/6 mice |
||
|
|
||
| Treated Groups |
Striatum |
Substantia nigra |
| MPTP |
0.27 ± 0.03 μg MPP+/g tissue |
0.28 ± 0.12 μg MPP+/g tissue |
| MPTP+ Losartan |
0.26+0.04 μg MPP+/g tissue |
0.22 ± 0.05 μg MPP+/g tissue |
|
|
||
| (b) Dopamine uptake in ventral mesencephalic cultures |
||
|
|
||
| Control |
68.1 ± 11.2 fmol/sec |
|
| Losartan (1 μM) |
72.7 ± 7.9 fmol/sec |
|
| Losartan (10 μM) |
76.2 ± 14.5 fmol/sec |
|
|
(a) MPP+ levels in the striatum and substantia nigra of C57BL/6 mice were measured by HPLC analysis 60 min after MPTP injection regimen and were compared to MPTP injected mice pretreated with the AT1 receptor antagonist losartan (n = 3). (b) Dopamine uptake levels in VM cultures treated with media control, 1 and 10 μM losartan (n = 3). | ||
Grammatopoulos et al. Molecular Neurodegeneration 2007 2:1 doi:10.1186/1750-1326-2-1 |
||